My Next Health

What My Next Health does

My Next Health Inc. (MNH) is a privately held, Delaware-incorporated healthcare technology company with operational headquarters in New York and a Canadian presence in Mississauga. The company builds health applications that deliver actionable genomic insights for the prevention and treatment of chronic diseases, serving three primary customer segments: healthcare providers and patients seeking point-of-care genomics reporting, pharmaceutical and biotech companies running clinical trials, and life sciences organizations pursuing AI-driven drug discovery and personalized treatment planning.

MNH's product portfolio is anchored by GEDI (Genomics Empowered Digitized Identity), a proprietary generative AI/ML platform that encodes genomic analytics derived from over 15,000 case studies conducted by the company's Scientific and Clinical Team under Chief Scientific Consultant Dr. Mansoor Mohammed. GEDI is integrated with IBM's quantum computing infrastructure to support drug discovery, drug simulation, digital twin modeling, and in-silico virtual clinical trials. Point-of-Care Genomics Reports focus on two functional areas: Genomics of Chronic Inflammation and Pain and Genomics of Infectious Diseases. The Clinical Trials Solutions product line supplies functional genomic assays, pharmacogenomic assays, and biomarkers for patient stratification in randomized trials. In 2024 the company extended into consumer health with a genomics-guided Remote Patient Monitoring program for chronic disease management.

MNH generates revenue primarily through genomics-report sales routed via healthcare providers to patients and through clinical trial services sold to pharmaceutical and biotech firms. The company's go-to-market is enterprise field sales, with named commercial customers including Hemostemix Inc. (clinical trial partnership) and, via the associated entity GNQ Insilico Inc., a physician-led North American health program under a three-year, US$96 million agreement. MNH is pursuing a public-market listing through GNQ Insilico's business combination with IB Acquisition Corp. (NASDAQ: IBAC), and has executed a Global Joint Initiative Marketing Agreement with IBM to co-deliver causal AI drug assessment and digital twin platforms. The firm is led by CEO Dr. Richard Heinzl (Harvard, Oxford) and Co-Founder/Chairman Rehan Huda, with a small operating team of 1-10 employees.

Name

My Next Health

Legal name

My Next Health Inc.

Website

https://mynexthealth.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

My Next Health builds a proprietary generative AI and quantum-enhanced genomics platform (GEDI) that delivers point-of-care genomic reports, clinical-trial stratification services, and drug-discovery simulations to healthcare providers, pharmaceutical companies, and biotech firms.

Ownership category

akta.pro rank

Product category

Precision Medicine Genomics Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Precision medicine
• Genomic analytics
• Clinical trial optimization
• AI drug discovery
• Healthcare genomics

Headquarters

HQ city

Mississauga

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Genomics Reports Sales: MNH launches genomics reports sold via healthcare providers to patients, engaging primary physicians in genomic dialogue for improved patient health outcomes.
2. Clinical Trial Services: Providing functional genomic assays, pharmacogenomic assays, and functional medical biomarkers to pharmaceutical companies and biotech firms conducting clinical trials. Enables refined patient stratification and better therapeutic allotment.
3. Subscription Investment: Hemostemix provided USD $150,000 subscription at CAD $0.25 per Unit to My Next Health.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

My Next Health deploys a genomic-based AI and quantum computing platform that scales proprietary genomic insights derived from over 15,000 case studies into precision medicine applications. The company sells point-of-care genomics reports through healthcare providers to patients and offers clinical trials solutions—including functional genomic assays and in-silico virtual clinical trials—to pharmaceutical and biotech firms. A genomics-guided Remote Patient Monitoring program for chronic disease management is being launched in the consumer health space.

Product overview

My Next Health is a healthcare technology company deploying an innovative genomic-based AI and quantum platform for clinical trials, point-of-care solutions, and personalized consumer health. The core offering consists of the GEDI (Genomics Empowered Digitized Identity) generative AI platform, which scales proprietary genomic insights derived from over 15,000 case studies through integration with IBM's quantum computing infrastructure. The Point-of-Care Genomics Reports enable healthcare providers to deliver actionable genomic insights to patients, focusing on chronic inflammation, pain, and infectious diseases. Clinical Trials Solutions leverage quantum-enabled drug discovery and in-silico virtual trials for pharmaceutical companies. These products work together to deliver precision medicine across drug development, clinical care, and consumer applications.

Differentiator

Problem solved

Functional benefit

Products and services

• GEDI (Genomics Empowered Digitized Identity) Platform A scalable generative AI machine learning platform encoding MNH's proprietary genomic analytics derived from 15,000+ case studies, integrating with IBM's quantum computing infrastructure to enable drug discovery, development, and in-silico clinical trials for pharmaceutical companies, biotech firms, and healthcare providers.
• Point-of-Care Genomics Reports Genomics reports sold via healthcare providers to patients focusing on two key functional genomic areas: Genomics of Chronic Inflammation & Pain and Genomics of Infectious Diseases. Includes physician training for report interpretation and healthcare plan integration to deliver actionable genomic insights at the point of care.
• Clinical Trials Solutions Quantum-enabled drug discovery and in-silico virtual clinical trials platform utilizing genetic stratification, epigenetic optimization, and MNH's physiologic, functional, and regulatory insights to improve patient outcomes with augmented safety and efficacy for pharmaceutical and biotech clinical programs.
• Genomics-Guided Remote Patient Monitoring Program A genomics-guided remote patient monitoring program for chronic disease management that extends MNH's proprietary genomic insights into the consumer health space for ongoing personalized care of patients with chronic conditions.

Quantifiable outcome

• Improved patient recruitment for clinical trials achieving both safety and efficacy results
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• IBMcoreTechnology or Integration · 1 March 2026Global Joint Initiative Marketing Agreement between GNQ Insilico and IBM to deliver causal AI Drug Assessment, Drug Simulation, and Digital Twin platforms. IBM provides consulting expertise and hybrid cloud deployment experience. Platforms integrate IBM's secured, scalable technology infrastructure with GNQ's mechanistic, causal AI models for precision medicine applications in drug development and clinical decision support.
• University of ReginacoreStrategic or Co-development Partner · 1 February 2022MNH provided $400,000 USD in-kind support to University of Regina's medical research team for NFL-funded research on concussion treatment and pain management using cannabinoids. Research led by Dr. Patrick Neary investigating CBD/THC formulations provided by My Next Health for pain management in those suffering from post-concussion syndrome and chronic pain.
• Hemostemix Inc.coreStrategic or Co-development Partner · 1 January 2022Global Master Services Agreement with Hemostemix Inc., a publicly traded autologous stem cell therapy company. MNH provides functional genomic assays, functional pharmacogenomic assays, and functional medical biomarkers. Hemostemix obtained a subscription from MNH in the amount of USD $150,000 at CAD $0.25 per Unit. Collaboration enables Hemostemix to recruit subjects into clinical trials who are best suited to achieve safety and efficacy results.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Lantern Pharma: AI-driven oncology drug development company using genomics and ML to identify patients for targeted therapies. Comparable smaller-scale AI genomics platform serving pharma.
• Ginkgo Bioworks: Cell engineering and biosecurity platform using automated labs and AI to program organisms for industrial and therapeutic applications. Comparable as an AI + biology platform play serving enterprise customers.

Direct peers

• Recursion Pharmaceuticals: AI-driven drug discovery platform combining proprietary biological data with ML models to accelerate pharmaceutical R&D. Directly comparable as a tech-forward biology platform targeting pharma trial cost reduction.
• Schrödinger: Computational drug discovery platform combining physics-based simulation with ML to identify and optimize therapeutic molecules. Comparable as a software/platform play serving pharma with precision-medicine positioning.
• Exscientia: AI-driven drug discovery company using generative AI and patient-derived data to design precision therapeutics. Closely comparable as an AI-first precision medicine platform.
• Insitro: ML-driven drug discovery company combining induced pluripotent stem cell biology with machine learning to predict drug behavior. Comparable as an AI-driven precision therapeutics platform.
• XtalPi: AI + quantum physics-powered drug discovery platform serving pharmaceutical companies with computational predictions of molecular behavior. Closely comparable as an AI + quantum pharma services platform.

Broad incumbents

• Tempus AI: Precision medicine company combining multi-modal data (genomics, imaging, clinical records) with AI to support diagnostics and pharma research. Comparable data-centric precision medicine approach with much larger scale.
• Veracyte: Genomic diagnostics company focused on molecular testing for cancer and other diseases, serving physicians and patients with actionable genomic insights. Comparable as a genomics-based diagnostics services provider.
• Foundation Medicine: Roche-owned molecular genomics profiling company providing comprehensive genomic testing to inform cancer treatment decisions. Comparable as a provider of physician-ordered genomic reports for clinical decision-making.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/my-next-health

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about My Next Health